Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06256367 · ClinicalTrials.gov registry record
Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder
A clinical trial of Bipolar I Disorder, sponsored by AbbVie.
- Completed
- Registry status
- 120
- Enrollment target
- 19
- Study locations
NCT06256367 is a study of Bipolar I Disorder that has completed, run by AbbVie. The registered enrollment target is 120 participants, below the 325-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target (63% lower). The trial reports 19 study locations across 11 states.
The verdict
NCT06256367, a study of Bipolar I Disorder, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
- 19
- Study locations
Study Summary
Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and quality of life outcomes in adult patients with BP-I experiencing a major depressive episode (with or without mixed features) requiring treatment and initiating treatment with cariprazine. It will examine outcomes of cariprazine treatment in a real-world setting in patients with BP-I commonly seen in clinical practices. Cariprazine (Vraylar) is a medication indicated in the United States and Canada to treat adult patients experiencing manic, mixed or depressive episodes associated with BP-I. This study plans to enroll approximately 170 adult patients with BP-I from the United States and Canada. Cariprazine should be prescribed by the physician under the usual and customary practice of physician prescription. The decision to initiate treatment with cariprazine should be made prior to, and independently from, the patient's decision to participate in the study. Participants will receive cariprazine as prescribed by their physician. Observational data will be collected during visits which should align to routine standard of care for a duration of up to 24 weeks.
Conditions Studied
Study Locations (19)
Ontario
- Chatham-Kent Clinical Trials /ID# 262414 - Chatham
- Grand River Hospital /ID# 263962 - Kitchener
- Sunny Johnson Medical Research Associates /ID# 267713 - Mississauga
- Southlake Regional Health Centre /ID# 264212 - Newmarket
- START Clinic for Mood and Anxiety Disorders /ID# 262416 - Toronto
Quebec
- Institut universitaire en santé mentale de Montréal /ID# 264665 - Montreal
- Clinique Woodward /ID# 264050 - Sherbrooke
- Douglas Mental Health University Institute /ID# 262048 - Verdun
California
- Bowman Medical Group /ID# 259989 - Beverly Hills
- UC Davis /ID# 259723 - Sacramento
Ohio
- Quest Therapeutics of Avon /ID# 259838 - Avon Lake
- North Star Medical Research LL /ID# 259730 - Middleburg Heights
Alabama
- University of Alabama at Birmingham - Main /ID# 260000 - Birmingham
Connecticut
- Montano Wellness LLC /ID# 259837 - Cromwell
Georgia
- Georgia Psychiatric Consultants & Advanced Discovery Research /ID# 259975 - Atlanta
Nebraska
- Omaha Insomnia and Psychiatric Services /ID# 259961 - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2026-01-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06256367
The ClinicalTrials.gov registry entry for NCT06256367 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 325-participant average among 26 other Bipolar I Disorder trials with a reported enrollment target (63% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar I Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06256367 reports 19 study locations spanning 11 distinct geographic areas - top geographies include Ontario, Quebec, California.
Frequently Asked Questions
What is clinical trial NCT06256367 about?
NCT06256367 is a clinical study titled "Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder". Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and ...
What is the current status of trial NCT06256367?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2024-04-18. Estimated completion is 2026-01-23.
What conditions does trial NCT06256367 study?
This clinical trial studies the following conditions: Bipolar I Disorder.
Who is sponsoring clinical trial NCT06256367?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06256367 being conducted?
This trial has 19 study locations across Alabama, California, Connecticut, Georgia, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar I Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
RECRUITING · Phase 2
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
RECRUITING · Phase 4
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.